細胞療法は、それが患者自身である場合もあるが、ドナーから健康な細胞を移植することによって、損傷した組織や細胞を置換または修復する効率的な方法として出現しています。過去 20 年ほどで、細胞療法の適用は拡大し、がんを含む多くの適応症をカバーするようになりましたが、その結果は期待を裏切らないものでした。T細胞療法は、がんを治療するための最も初期の細胞ベース療法として開発され、長年にわたってこの領域で多くの改善が行われ、患者のがんと戦うためにより多くの免疫細胞が侵入できるようになりました。NK細胞は、固形がん、血液がんのいずれの治療にも利点を有する最も新しい種類の免疫細胞であり、さらなる改善によって、今後数年間で細胞療法市場で圧倒的なシェアを占めるようになると予想されます。
目次
1. Introduction to Natural Killer (NK) Cell Therapy
2. Mechanism of Action of NK Cell Therapy
2.1 Cytotoxic Action of NK Cells
2.2 Working of NK Cell Therapy
2.3 NK Cell Therapies Approaches
2.3.1 CAR NK Cell Therapies
2.3.2 TCR NK Cell Therapies
3. Treatment Strategies For NK Cell Therapies
3.1 NK Cell Therapy As Monotherapy
3.2 NK Cell Therapy As Combinatorial Agent
4. Application of NK Cell Therapy By Indication
4.1 NK Cell Therapy For Cancer
4.2 COVID-19 and Other Viral Infections
5. NK Cell Therapy Characteristics Enhancement Approaches
5.1 Use Of Nanotechnology
5.2 Modifications In CARs
5.3 Use Of CRISPR/Cas9 Gene Editing
6. Global Natural Killer Cell Therapies Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
7. Global Natural Killer Cell Therapies Clinical Trials By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
8. NK Cell Based Therapy Proprietary Technologies Insight
8.1 Overview
8.2 Proprietary Technologies By Company
9. Partnerships and Funding for NK Cell Therapies
9.1 Recent Partnerships, Collaborations and Licensing Agreements
9.2 Funding Deals By Companies
10. Investigational NK Cell Therapies With FDA Designations
10.1 FDA Fast Track Designation
10.2 FDA Orphan Drug Designation
11. NK Cell Therapies Market Trends and Clinical Trials Outlook
11.1 Current Market Trends, Developments and Clinical Trials Assessment
11.2 Future Commercialization Opportunity
12. Competitive Landscape
12.1 Acepodia
12.2 Beijing JD Biotech
12.3 Cartherics
12.4 Catamaran Bio
12.5 Century Therapeutics
12.6 City of Hope National Medical Center
12.7 CRISPR Therapeutics
12.8 CytoImmune Therapeutics
12.9 Cytovia Therapeutics
12.10 Dragonfly Therapeutics
12.11 Editas Medicine
12.12 Fate Therapeutics
12.13 Gamida-Cell
12.14 GC Biopharma/GC Lab Cell
12.15 GICELL
12.16 Glycostem
12.17 HK inno.N
12.18 ImmunityBio
12.19 Karolinska Institute
12.20 Kiadis Pharma
12.21 Nkarta Therapeutics
12.22 NKGen Biotech
12.23 ONK Therapeutics
12.24 Phio Pharmaceuticals
12.25 Sanofi
12.26 Senti Biosciences
12.27 Shoreline Biosciences
12.28 Sian Wuhan Medical Technology
12.29 Smart Immune
12.30 Sorrento Therapeutics
12.31 Therabest Korea
12.32 University of California
12.33 University Of Minnesota
12.34 University of Texas M. D. Anderson Cancer Center
12.35 XNK Therapeutics
12.36 Zelluna Immunotherapy
List of Figures & Tables
Figure 1-1: NK Cells - Identification and Discovery Timeline
Figure 1-2: NK Cell Subsets - CD56low/dim v/s CD56bright
Figure 2-1: Cytotoxic Action Of NK Cells
Figure 2-2: CAR-NK Cells Preparation
Figure 2-3: Delivery Of CAR Gene Into NK Cell
Figure 2-4: NK Cells Sources For Therapy
Figure 2-5: Structure Of CAR/TCR-NK Cell
Figure 4-1: AB-101 Phase 1/2 Study - Initiation and Completion Years
Figure 4-2: SMT-NK Phase 2/3 Study - Initiation and Completion Years
Figure 4-3: CYNK-001 Phase 1 CYNK001AML01 Study - Initiation and Completion Years
Figure 4-4: CYNK-001 Phase 1 Study - Initiation and Completion Years
Figure 4-5: CYNK-101 Phase 1/2 Study - Initiation and Completion Years
Figure 4-6: FT538 Phase 1 Study - Initiation and Completion Years
Figure 4-7: CYNK-001 Phase 1/2 CYNKCOVID Study - Initiation and Completion Years
Figure 4-8: DVX201 Phase 1 Study - Initiation and Completion Years
Figure 4-9: FT538 Phase 1 Study - Initiation and Completion Years
Figure 5-1: Improvements In NK Cell Therapy Using Nanotechnology
Figure 5-2: Basic Structure Of CARs On NK Cell
Figure 5-3: Gene Editing Tools
Figure 6-1: Global - NK Cell Therapies Clinical Trials By Company, 2023 till 2028
Figure 6-2: Global - NK Cell Therapies Clinical Trials By Country, 2023 till 2028
Figure 6-3: Global - NK Cell Therapies Clinical Trials By Indication, 2023 till 2028
Figure 6-4: Global - NK Cell Therapies Clinical Trials By Patient Segment, 2023 till 2028
Figure 6-5: Global - NK Cell Therapies Clinical Trials By Phase, 2023 till 2028
Figure 8-1: Artiva Biotherapeutics - Proprietary CAR-NK Cell Platform
Figure 8-2: Artiva Biotherapeutics - Proprietary AlloNKTM NK Cell Therapy Scaling Platform
Figure 8-3: Catamaran Bio - Proprietary Tailwindandreg; Platform
Figure 8-4: GAIA BioMedicine - Proprietary NK Cell Therapy Working Mechanism
Figure 8-5: GAIA BioMedicine - Proprietary Technologies’ Salient Features
Figure 8-6: Gamida Cell - NK Cell Therapy Manufacturing Process
Figure 8-7: HebeCell - Proprietary Scalable NK Cell Technology
Figure 8-8: ImmunityBio - Proprietary haNKandreg; Cell Structure
Figure 8-9: Nkarta - Proprietary CAR-NK Cell Structure
Figure 8-10: Nkarta - Proprietary NK Cell Therapy Platform
Figure 8-11: Senti Biosciences - Gene Circuit Technology Platform
Figure 8-12: Senti Biosciences - Gene Circuit Technology Platform Applicability
Figure 8-13: Wugen - Proprietary Memory NK Cell Platform
Figure 8-14: XNK Therapeutics - Autologous NK Cell Therapy Platform
